Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662539 · ClinicalTrials.gov registry record · Phase 2
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
A Phase 2 study, sponsored by Zealand Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 493
- Enrollment target
NCT06662539 is a Phase 2 study that has completed, run by Zealand Pharma. The registered enrollment target is 493 participants.
The verdict
NCT06662539, a Phase 2 study, has completed, sponsored by Zealand Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 493 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
Interventions
- DRUG Placebo
- DRUG Petrelintide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 493 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2026-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06662539
The ClinicalTrials.gov registry entry for NCT06662539 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 493 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06662539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06662539 about?
NCT06662539 is a clinical study titled "Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities". The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
What is the current status of trial NCT06662539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 493 participants. The study started on 2024-12-09. Estimated completion is 2026-03-07.
What interventions are being tested in trial NCT06662539?
The interventions under investigation include: Placebo (DRUG), Petrelintide (DRUG).
Who is sponsoring clinical trial NCT06662539?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.